Cognitive impairment and electroconvulsive therapy in geriatric depression, what could be the role of rivastigmine? A case series

Cognitive impairment and electroconvulsive therapy in geriatric depression, what could be the role of rivastigmine? A case series

Electroconvulsive therapy (ECT), albeit highly effective in treating depression, is frequently associated with cognitive impairment, either temporary or more persistent. Especially in older patients, who generally respond even better, serious cognitive impairment during the course of ECT may lead to...

Full description

Bibliographic Details
Main Authors:	Audrey Monica van Schaik, Didi Rhebergen, Marieke Jantien Henstra, Daniel J. Kadouch, Eric van Exel, Maximilianus Lourentius Stek
Format:	Article
Language:	English
Published:	MDPI AG 2015-09-01
Series:	Clinics and Practice
Subjects:	Depression cognitive impairment electroconvulsive therapy elderly acetylcholinesterase inhibitor rivastigmine.
Online Access:	https://www.clinicsandpractice.org/index.php/cp/article/view/780

Similar Items

Evaluation of donepezil and rivastigmine administration on the cognitive deficits induced by electroconvulsive therapy: A randomized, double-blind clinical trial
by: Masoumeh Nazarinasab, et al.
Published: (2019-11-01)

Acetylcholinesterase activity in the pons and medulla oblongata of rats after chronic electroconvulsive shock
by: R. Camarini, et al.
Published: (1997-10-01)

Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia
by: Kandiah N, et al.
Published: (2017-04-01)

Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease
by: Davide V Moretti, et al.
Published: (2014-07-01)

Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia
by: Yoon-Sang Oh, et al.
Published: (2015-05-01)

The specific features of using a rivastigmine transdermal formulation in Alzheimer’s disease
by: Elena Evgenyevna Vasenina, et al.
Published: (2012-09-01)

Formulation and Evaluation of Eudragit RL-100 Nanoparticles Loaded In-Situ Forming Gel for Intranasal Delivery of Rivastigmine
by: Sara Salatin, et al.
Published: (2020-01-01)

Direct Asymmetric Reductive Amination for the Synthesis of (S)-Rivastigmine
by: Guorui Gao, et al.
Published: (2018-08-01)

Effects of rivastigmine and memantine alone and in combination on learning and memory in rats with scopolamine-induced amnesia
by: Yanev Peter Georgiev, et al.
Published: (2015-09-01)

Investigating the effect of rivastigmine on postural control in Parkinson's disease dementia
by: McDonald, Jaime
Published: (2018)

Visual Hallucinations Due to Rivastigmine Transdermal Patch Application in Alzheimer's Disease; The First Case Report
by: Yıldız Değirmenci, et al.
Published: (2016-12-01)

Systematic development of lectin conjugated microspheres for nose-to-brain delivery of rivastigmine for the treatment of Alzheimer’s disease
by: Yang Gao, et al.
Published: (2021-09-01)

USE OF A RIVASTIGMINE TRANSDERMIC PATCH IN ALZHEIMER’S DISEASE AND PARKINSON’S DISEASE DEMENTIA
by: Lacramioara Perju Dumbrava, et al.
Published: (2009-03-01)

Cognitive impairment in psychiatric patients receiving electroconvulsive therapy
by: Alijanpour Ebrahim, et al.
Published: (2019-01-01)

Rivastigmine patch (Exelon patch) compared to melatonin patch in prevention of postoperative delirium in the elderly
by: Rania Maher Hussien, et al.
Published: (2020-08-01)

Electroconvulsive therapy: old acquaintance for the youngster or new opportunity for the elder? Review of the literature and applications in the geriatric population
by: Massimo Palleschi, et al.
Published: (2019-12-01)

In situ-forming injectable organogel implant for sustained release of rivastigmine
by: Vintiloiu, Anda
Published: (2016)

Patients’, Carers’, and the Public’s Perspectives on Electroconvulsive Therapy
by: Chris Griffiths, et al.
Published: (2019-05-01)

Preparation and performance of a colorimetric biosensor using acetylcholinesterase and indoxylacetate for assay of nerve agents and drugs
by: Pohanka Miroslav, et al.
Published: (2014-12-01)

Influence of Rivastigmine transdermal on butyrylcholinesterase levels in patients with Alzheimer's disease
by: Gustavo Alves Andrade dos Santos, et al.

Status epilepticus following electroconvulsive therapy
by: T M Omprakash, et al.
Published: (2013-01-01)

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
by: Dan-Dan Li, et al.
Published: (2019-05-01)

Electroconvulsive therapy in the elderly and nonelderly: 10 years' retrospective comparison
by: Ravishankar Vinutha, et al.
Published: (2017-01-01)

Electroconvulsive therapy in geriatric patients: A literature review and program report from Virginia Commonwealth University, Richmond, Virginia, USA
by: Andrew D Snyder, et al.
Published: (2017-01-01)

Chart review of electroconvulsive therapy practice from a tertiary care geriatric mental health set up
by: Akanksha Sonal, et al.
Published: (2017-01-01)

Adverse drug events affecting medication persistence with rivastigmine patch application
by: Osada T, et al.
Published: (2018-07-01)

Effet des inhibiteurs d'acétylcholinestérase sur le fonctionnement cognitif dans la schizophrénie
by: Chouinard, Sylvie
Published: (2009)

The Effect of Vascular Risk Factors on the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer’s Disease
by: M.R. Farlow, et al.
Published: (2011-06-01)

Combination of Cholecalciferol and Rivastigmine Improves Cognitive Dysfunction and Reduces Inflammation in STZ Induced Alzheimer's Model Experimentally in Rats
by: Amany N. Ibrahim, et al.
Published: (2018-07-01)

Trends in use of electroconvulsive therapy among geriatric patients over a period of 9 years at a tertiary care center in North India
by: Sandeep Grover, et al.
Published: (2017-01-01)

In Situ<i>-</i>Forming Microparticles for Controlled Release of Rivastigmine: In Vitro Optimization and In Vivo Evaluation
by: Mohamed Haider, et al.
Published: (2021-01-01)

Whole-Cell Biocatalyst for Chemoenzymatic Total Synthesis of Rivastigmine
by: Paola Vitale, et al.
Published: (2018-01-01)

The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer’s Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study
by: Yatawara C, et al.
Published: (2021-02-01)

Effects of a Rivastigmine Patch on Self-Care Activities in Patients with Alzheimer's Disease plus Cerebrovascular Disease
by: Yong Kyun Kim, et al.
Published: (2014-10-01)

Intensification of the alcohol withdrawal syndrome by antecedent electroconvulsive shocks
by: Van Oot, Peter H.
Published: (2010)

Factors affecting therapeutic response to Rivastigmine in Alzheimer's disease patients in Taiwan
by: Tzu-Hua Chen, et al.
Published: (2017-06-01)

Design, synthesis and evaluation of genistein-polyamine conjugates as multi-functional anti-Alzheimer agents
by: Xin Zhang, et al.
Published: (2015-01-01)

Electroconvulsive therapy in the elderly
by: Sandeep Grover, et al.
Published: (2017-01-01)

Anaesthesia for electroconvulsive therapy: An overview with an update on its role in potentiating electroconvulsive therapy
by: Pavan Kumar Kadiyala, et al.
Published: (2017-01-01)

Electroconvulsive stimulation and hippocampal synaptic plasticity
by: Stewart, Caroline A.
Published: (1994)